NCT02016755View on ClinicalTrials.gov

A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Critical Limb IschemiaVascular DiseasesPeripheral Arterial Disease
Interventions
BIOLOGICAL

HGF Plasmid

Intramuscular injection in the affected limb.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

AnGes USA, Inc.

INDUSTRY

NCT02016755 - A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia | Biotech Hunter | Biotech Hunter